Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study.
Women with thrombophilia and a history of recurrent pregnancy loss have poor pregnancy outcomes. Prophylaxis with enoxaparin 40 mg/day or 80 mg/day resulted in favorable gestational and neonatal outcomes.
Brenner
Benjamin
B
Rambam Medical Center, Haifa, Israel. b_brenner@rambam.health.gov.il
Bar
Jacob
J
Ellis
Martin
M
Yarom
Ilan
I
Yohai
David
D
Samueloff
Aaron
A
D000026:Abortion, Habitual / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D050498:Live Birth / Q000453:epidemiology*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D011256:Pregnancy Outcome / Q000453:epidemiology; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D019851:Thrombophilia / Q000188:drug therapy* / Q000453:epidemiology
D017984:Enoxaparin